617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: MRD and Novel molecular Markers
Watch Session
272 The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)Natasha S Anstee, Giovanna Pomilio, Mark Levis, et al.
Maximilian Stahl, Andriy Derkach, Christopher Famulare, et al.
Rhonda E. Ries, Timothy Junius Triche Jr., Jenny L. Smith, et al.
Julia K. Herzig, Frank G. Rücker, Laura K. Schmalbrock, et al.
Abhishek Maiti, Courtney D. DiNardo, Sa A Wang, et al.
Ing Soo Tiong, Richard Dillon, Adam Ivey, et al.